-
Journal of Clinical Neuroscience :... Dec 2019Rhabdomyolysis is characterized by the rupture of skeletal muscles due to a lot of reasons such as exercise, drug addiction, toxins, infections, trauma and some...
Rhabdomyolysis is characterized by the rupture of skeletal muscles due to a lot of reasons such as exercise, drug addiction, toxins, infections, trauma and some medications. The etiology of postoperative rhabdomyolysis is potentially multifactorial and has been documented in several types of surgery. The lysis of cell membrane releases organic and inorganic intracellular components that can be toxic and life threatening. Creatinephosphokinase (CPK) is one of the components and it is the most sensitive indicator of myocyte injury. The classic triad of symptoms is characterized by myalgia, weakness and brown-red urine. There is not a clearly agreed level of serum CPK that is evident for diagnosis of rhabdomyolysis. However, a CPK level higher than 5 times of its normal value is accepted by many authors as diagnostic criteria. Acute kidney injury is the most serious complication of rhabdomyolysis in the days following initial presentation and develops in 33% of patients. The objective of this study was to perform a review of the literature, aiming at a better understanding about the changes in CPK levels and the frequency of rhabdomyolysis in spine surgery, with special attention in posterior lumbar fusion. Nineteen studies were selected for analysis. The studies had different characteristics considering patients age, body mass index, comorbidities and type of surgery. The best available evidence points out to the prognosis depend on the extension and clinical severity of rhabdomyolysis, as well as on the early and prompt medical intervention.
Topics: Adult; Female; Humans; Lumbar Vertebrae; Male; Postoperative Complications; Rhabdomyolysis; Risk Factors; Spinal Fusion
PubMed: 31447366
DOI: 10.1016/j.jocn.2019.08.034 -
Current Molecular Pharmacology 2020Nipah virus (NiV) and Hendra virus (HeV) of genus Henipavirus are the deadliest zoonotic viruses, which cause severe respiratory ailments and fatal encephalitis in...
BACKGROUND
Nipah virus (NiV) and Hendra virus (HeV) of genus Henipavirus are the deadliest zoonotic viruses, which cause severe respiratory ailments and fatal encephalitis in humans and other susceptible animals. The fatality rate for these infections had been alarmingly high with no approved treatment available to date. Viral attachment and fusion with host cell membrane is essential for viral entry and is the most essential event of viral infection. Viral attachment is mediated by interaction of Henipavirus attachment glycoprotein (G) with the host cell receptor: Ephrin B2/B3, while viral fusion and endocytosis are mediated by the combined action of both viral glycoprotein (G) and fusion protein (F).
CONCLUSION
This review highlights the mechanism of viral attachment, fusion and also explains the basic mechanism and pathobiology of this infection in humans. The drugs and therapeutics used either experimentally or clinically against NiV and HeV infection have been documented and classified in detail. Some amino acid residues essential for the functionality of G and F proteins were also emphasized. Therapeutic designing to target and block these residues can serve as a promising approach in future drug development against NiV and HeV.
Topics: Animals; Antiviral Agents; Drug Design; Hendra Virus; Henipavirus Infections; Humans; Nipah Virus; Virus Internalization
PubMed: 31657692
DOI: 10.2174/1874467212666191023123732 -
Journal of Cellular Physiology Apr 2021Due to the rapidly spreading of novel coronavirus disease (COVID-19) worldwide, there is an urgent need to develop efficient vaccines and specific antiviral treatments....
Due to the rapidly spreading of novel coronavirus disease (COVID-19) worldwide, there is an urgent need to develop efficient vaccines and specific antiviral treatments. Pathways of the viral entry into cells are interesting subjects for targeted therapy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present study aims to provide a systematic evaluation of the most recent in vitro and in vivo investigations targeting SARS-CoV-2 cell entry. A systematic search was carried out in major medical sources, including MEDLINE (through PubMed), Web of Science, Scopus, and EMBASE. Combinations of the following search terms were used: SARS-CoV-2, in vitro, in vivo, preclinical, targeted therapy, and cell entry. A modified version of the Consolidated Standards of Reporting Trials and Systematic Review Centre for Laboratory Animal Experimentation assessment tools were applied for evaluating the risk of bias of in vitro and in vivo studies, respectively. A narrative synthesis was performed as a qualitative method for the data synthesis of each outcome measure. A total of 2,649 articles were identified through searching PubMed, Web of Science, Scopus, EMBASE, Google Scholar, and Biorxiv. Finally, 22 studies (one in vivo study and 21 in vitro studies) were included. The spike (S) glycoprotein of the SARS-CoV-2 was the main target of investigation in 19 studies. SARS-CoV-2 can enter into the host cells through endocytosis or independently. SARS-CoV-2 S protein utilizes angiotensin-converting enzyme 2 or CD147 as its cell-surface receptor to attach host cells. It consists of S1 and S2 subunits. The S1 subunit mediates viral attachment to the host cells, while the S2 subunit facilitates virus-host membrane fusion. The cleavage of the S1-S2 protein, which is required for the conformational changes of the S2 subunit and processing of viral fusion, is regulated by the host proteases, including cathepsin L (during endocytosis) and type II membrane serine protease (independently). Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms fall into four main categories: strategies targeting virus receptors on the host, strategies neutralizing SARS-CoV-2 spike protein, strategies targeting virus fusion to host cells, and strategies targeting endosomal and non-endosomal dependent pathways of virus entry. Inhibition of the viral entry by targeting host or virus-related components remains the most potent strategy to prevent and treat COVID-19. Further high-quality investigations are needed to assess the efficacy of the proposed targets and develop specific antivirals against SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Humans; SARS-CoV-2; Virus Internalization; COVID-19 Drug Treatment
PubMed: 32901936
DOI: 10.1002/jcp.30032 -
Life Sciences Jun 2024Liposomes, as a colloidal drug delivery system dating back to the 1960s, remain a focal point of extensive research and stand as a highly efficient drug delivery method.... (Review)
Review
Liposomes, as a colloidal drug delivery system dating back to the 1960s, remain a focal point of extensive research and stand as a highly efficient drug delivery method. The amalgamation of technological and biological advancements has propelled their evolution, elevating them to their current status. The key attributes of biodegradability and biocompatibility have been instrumental in driving substantial progress in liposome development. Demonstrating a remarkable ability to surmount barriers in drug absorption, enhance stability, and achieve targeted distribution within the body, liposomes have become pivotal in pharmaceutical research. In this comprehensive review, we delve into the intricate details of liposomal drug delivery systems, focusing specifically on their pharmacokinetics and cell membrane interactions via fusion, lipid exchange, endocytosis etc. Emphasizing the nuanced impact of various liposomal characteristics, we explore factors such as lipid composition, particle size, surface modifications, charge, dosage, and administration routes. By dissecting the multifaceted interactions between liposomes and biological barriers, including the reticuloendothelial system (RES), opsonization, enhanced permeability and retention (EPR) effect, ATP-binding cassette (ABC) phenomenon, and Complement Activation-Related Pseudoallergy (CARPA) effect, we provide a deeper understanding of liposomal behaviour in vivo. Furthermore, this review addresses the intricate challenges associated with translating liposomal technology into practical applications, offering insights into overcoming these hurdles. Additionally, we provide a comprehensive analysis of the clinical adoption and patent landscape of liposomes across diverse biomedical domains, shedding light on their potential implications for future research and therapeutic developments.
Topics: Animals; Humans; Cell Membrane; Drug Delivery Systems; Liposomes; Tissue Distribution
PubMed: 38599316
DOI: 10.1016/j.lfs.2024.122616